FDAsafety guidance66% confidence
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Chattem Sanofi; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Allergy · Antihistamine
- Sub-indication
- Ild
Related signal: FDA Approves Supplemental Application for Children's Allegra Hives